총 3,026건

해외임상승인현황 정보 :: 순번, 임상시험 제목, 적응증, 연구설계, 의뢰자/실시기관, 임상단계, 게시일자
순번 임상시험 제목 적응증 연구설계 의뢰자/실시기관 임상단계 게시일자
1 Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma|Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 Drug: Cyclophosphamide|Biological: IRX-2|Biological: Nivolumab|Procedure: Surgery Emory University|Bristol-Myers Squibb|Brooklyn ImmunoTherapeutics, LLC Phase 1 2020-07-01
2 An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease Non-Small Cell Lung Cancer|Non-Small-Cell Lung Carcinoma|Circulating Tumor DNA Biological: Nivolumab|Drug: Vinorelbine|Drug: Gemcitabine|Drug: Docetaxel|Drug: Pemetrexed|Drug: Cisplatin|Drug: Carboplatin|Drug: Paclitaxel|Other: Observation Bristol-Myers Squibb Phase 2 2020-06-15
3 Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy Epithelial Ovarian Cancer|Primary Peritoneal Carcinoma|Fallopian Tube Cancer Drug: AVB-S6-500|Drug: Paclitaxel|Drug: Carboplatin|Procedure: Tissue from Diagnostic Laparoscopy|Procedure: Tissue from Core biopsy|Procedure: Interval Debulking|Procedure: Peripheral blood|Procedure: Ascites collection Washington University School of Medicine|Aravive, Inc. Phase 1 2019-12-31
4 PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma Renal Cell Carcinoma Drug: Durvalumab|Drug: Tremelimumab|Device: TDS-IM System|Biological: Neoantigen DNA Vaccine|Procedure: Research blood draw Washington University School of Medicine|MedImmune LLC Phase 2 2019-10-31
5 Distribution of a Single IV Dose Of [124I]-Pf 06687234 and Pf 06687234 Assessed With PET-CT Imaging In Moderate To Severe Ulcerative Colitis Ulcerative Colitis Biological: PF 06687234|Biological: [124I]IB PF 06687234 Pfizer Phase 1 2019-10-15
6 Interleukin 6 Blockade Modifying Antibody-Mediated Graft Injury and Estimated Glomerular Filtration Rate (eGFR) Decline Antibody-mediated Rejection Biological: Clazakizumab|Drug: Normal saline Vitaeris INC|ICON Clinical Research Phase 3 2019-09-01
7 Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma Uveal Melanoma Radiation: Stereotactic Body Radiation Therapy|Biological: Ziv-Aflibercept Sidney Kimmel Cancer Center at Thomas Jefferson University|Regeneron Pharmaceuticals|Thomas Jefferson University Phase 2 2019-08-09
8 DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab Glioblastoma Biological: Human CMV pp65-LAMP mRNA-pulsed autologous DCs|Drug: Temozolomide|Biological: Varlilumab|Biological: Td|Biological: 111In-labeled DCs|Biological: Unpulsed DCs|Biological: HIV-Gag mRNA-pulsed autologous DCs Gary Archer Ph.D.|Celldex Therapeutics|Duke University Phase 2 2019-07-22
9 Gene Therapy for Achromatopsia (CNGA3) Achromatopsia Biological: AAV- CNGA3 MeiraGTx UK II Ltd Phase 1|Phase 2 2019-07-18
10 A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD Acute-graft-versus-host Disease|aGVHD|GVHD|GVHD, Acute Biological: EQ001|Biological: EQ001 Placebo Equillium|Biocon Limited Phase 1|Phase 2 2019-07-15